Those outcomes compare to previous information showing an efficacy rate of around 94 percent at preventing infections. In between May 2 and June 5, the vaccine was 98 percent reliable at avoiding hospitalizations for coronavirus infection.
Public Health England on July 2 stated information recommends vaccine efficiency against symptomatic illness from one dose of the vaccines in use provides in between 55 to 70 percent efficacy. Data on two doses suggests efficiency of around 65 to 90 percent.
In the time between the 2 datasets, the country has lifted lockdown limitations at the very same time as the arrival of the Delta variation, which is more transmissible.
From June 6 to July 2, the vaccine showed 64 percent efficacy at preventing cases and 94 percent reliable at avoiding hospitalizations, the Israeli health ministry announced late Monday, according to Ynet news.
The BioNTech/Pfizer vaccine appears less efficient at preventing COVID-19 cases resulting from the Delta coronavirus variant however stays highly effective at avoiding hospitalization, according to early data from Israel.
Data from the U.K. has actually also suggested that vaccines are less reliable at avoiding infections with the Delta variation, but that they remain efficient at avoiding serious disease.
This short article is part of POLITICOs premium policy service: Pro Health Care. From drug rates, EMA, vaccines, pharma and more, our specialized reporters keep you on top of the topics driving the health care policy agenda.